A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

• Status: RECRUITING
• Trial end date: 2026-12-01

Summary

This is a randomized, double-blind, multicenter, Phase 3 study to compare the efficacy and safety of LY01015 and Opdivo®（Nivolumab Injection）combined respectively with fluorouracil plus cisplatin in participants with unresectable advanced, recurrent or metastatic previously untreated esophageal squamous cell carcinoma.

• Phase: PHASE3

Details

• Lead Sponsor: Shandong Boan Biotechnology Co., Ltd
• Treatments: Cisplatin; Fluorouracil; Nivolumab